The Pharma Data

JANUARY 3, 2021

Ltd (“ CIMC Sanctum “) recently started R&D of liquid nitrogen biological containers for long-term cryogenic storage of vaccines, stem cells, plasma, semen, embryos and various tissues and organs for the needs of the biomedical industry. The equipment is specifically developed for cryogenic storage of biological samples.

Containment 40

Containment Vaccination Vaccine Marketing 40

Pharmaceutical Technology

SEPTEMBER 5, 2022

The list also includes providers of behavioural insights, brand naming and development solutions, commercial recruiting solutions, digital and social media advertising, full-service commercial, medical communications, and several other solutions and products.

Marketing 130

Marketing Compliance Doctors Doctor 130

Scienmag

MAY 28, 2021

Genetics toolkit targets less researched Culex mosquitoes, which transmit West Nile virus and avian malaria Credit: Gantz Lab, UC San Diego Since the onset of the CRISPR genetic editing revolution, scientists have been working to leverage the technology in the development of gene drives that target pathogen-spreading mosquitoes such as Anopheles and (..)

Containment 69

Containment Genetics Research Gene 69

Pharmaceutical Technology

SEPTEMBER 7, 2022

The download contains detailed information on the providers and their services and solutions, alongside contact details to aid your purchasing decision. The AI engine predicts and identifies patients who are at risk and optimises interventions for them by channel, messages and timing. Patient adherence.

Pharmacy 130

Pharmacy Containment Manufacturing Compliance 130

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-2138 is under clinical development by Xencor and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Antibody 100

Antibody Engineer Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-2138 is under clinical development by Xencor and currently in Phase I for Gastric Cancer. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. The drug candidate is being developed based on XmAb technology.

Antibody 100

Antibody Engineer Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-2138 is under clinical development by Xencor and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Antibody 100

Antibody Engineer Clinical Trials Clinical Trials 100

Pharmaceutical Technology

MARCH 10, 2023

The document contains detailed information on the suppliers and their product offerings, alongside contact details to aid your purchasing decision. Role of freeze-drying systems in the pharmaceutical industry The pharmaceutical freeze-drying market is highly governed by stringent standards and laws.

Manufacturing 147

Manufacturing Production Containment Antibody 147

XTalks

MARCH 21, 2024

In this episode of the Xtalks Food Podcast, Sydney talks about the new offerings, which were developed in collaboration with NotCo, a Chilean food-tech firm renowned for its AI-driven approach to crafting plant-based food solutions. The products contain ingredients like bamboo fiber, pea protein and mushrooms.

Genetic Engineering 98

Genetic Engineering Production Engineer Containment 98

Scienmag

JANUARY 22, 2021

Credit: LI Sushuang Nanofiltration (NF) is an advanced technology for treating wastewater containing organic micropollutants (OMPs). WAN Yinhua from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences developed a stable graphene oxide nanofiltration membrane with uniform pore size to remove OMPs.

Engineer 52

Engineer Containment Development Research 52

pharmaphorum

JANUARY 24, 2022

The expanding production of high potency APIs, along with the increase in associated toxicities, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety. Assess engineering containment controls, from isolators and barriers to fully automated lines.

Containment 52

Containment Engineer Contamination Manufacturing 52

Drug Discovery World

JANUARY 9, 2023

Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity. . Using gene engineering, we are repurposing cancer cells to develop a therapeutic that kills tumour cells and stimulates the immune system to both destroy primary tumors and prevent cancer.” .

Scientist 52

Scientist Gene Editing Gene Engineer 52

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

OCTOBER 26, 2020

This work complements the Company’s own development work currently being undertaken. This additional extension of the collaboration will allow us to choose the best CDX antibody for pre-clinical and clinical development.” ” Market Abuse Regulation (MAR) Disclosure.

Development 40

Development Antibody Engineer Production 40

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

The Pharma Data

JANUARY 12, 2021

LONDON, UK / ACCESSWIRE / January 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company (“GlobalCo”).

Antibody 40

Antibody Development Licensing Licensing 40

Pharmaceutical Technology

SEPTEMBER 14, 2022

Successful TIL therapy depends on the infusion product containing tumour-reactive T cells that, on infusion, generate an anti-tumour immune response that causes disease regression. The use of engineered immune cytokines that selectively induce the expansion of TILs is being investigated as an alternative to IL-2 stimulation.

Immune Response 246

Immune Response In-Vivo Production Manufacturing 246

The Pharma Data

JANUARY 4, 2021

Sanofi will be responsible for all future development, manufacturing and commercialization of IPH6101/SAR443579. We believe IPH6101/SAR443579 is the first NKp46-based NK cell engager to start development, demonstrating the next wave of scientific innovation at Innate. Eric Vivier, PhD, Chief Scientific Officer at Innate Pharma. “We

Development 52

Development Antibody Drugs Containment 52

Scienmag

SEPTEMBER 13, 2021

DNA is the instruction manual for every living organism, guiding the development and functioning of all biological processes. In essence, it is a molecule with a double helix structure with each unit of a helix containing what are known as “DNA bases”.

DNA 62

DNA Scientist Containment Development 62

The Pharma Data

MARCH 4, 2021

Takeda will assume sole responsibility for further worldwide development and commercialization, and Ovid will no longer have any financial obligation to Takeda under the original collaboration agreement, including for milestone payments or any future development and commercialization costs.

Development 52

Development Containment Medicine Clinical Trials 52

pharmaphorum

NOVEMBER 17, 2021

The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products. Daniel Latham, Head Connected Health Product Development, Novartis. Louise Place, Director, Devices, GSK.

Drugs 52

Drugs Drug Delivery Engineer Production 52

XTalks

JUNE 26, 2023

A study by Victor Lobanov and co-authors, published last week in the journal Aquacultural Engineering , sheds light on this groundbreaking achievement. Lobanov emphasized the significance of fish feces, stating , “Fish waste contains a lot of nutrients.

Production 98

Production Engineer Doctors Doctor 98

FDA Law Blog

FEBRUARY 7, 2023

For PMA devices, the marketing application contains quality system and manufacturing information, so getting started on the quality system in parallel to device development is important for a timely submission. There is one section of the QMS, however, that is worth starting early in the product development lifecycle: Design Controls.

Compliance 98

Compliance Marketing Regulation Development 98

The Pharma Data

NOVEMBER 22, 2020

Omecamtiv mecarbil is an investigational cardiac myosin activator, developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF), and was recently studied in GALACTIC-HF, a positive Phase 3 cardiovascular outcomes clinical trial. Terms of Termination. GALACTIC-HF : Results and Next Steps.

Development 52

Development Clinical Trials Clinical Trials Trials 52

XTalks

MAY 12, 2022

Engineers at the University of California, San Diego (UCSD) developed a prototype of a wearable sensor for continuous monitoring of glucose, alcohol and lactate. The UCSD researchers published an article on May 9 in Nature Biomedical Engineering that describes their new device. Engineering a Continuous Monitoring Device.

Engineer 59

Engineer Development Containment Regulation 59

Scienmag

DECEMBER 15, 2020

But this ash often contains significant amounts of precious metals, such as zinc. A unique method developed by researchers at Chalmers University of Technology, Sweden, […].

Containment 52

Containment Development Research Engineer 52

Roots Analysis

FEBRUARY 26, 2024

The famous Indian physician, Sushruta, wrote the Sushruta Samhita , a medical guide that contains descriptions of approximately 1120 illnesses, 700 medicinal plants, 64 medicinal preparations from mineral sources and 57 therapeutic preparations from animal sources. The science of vaccinology has evolved significantly since Jenner’s discovery.

Genetics 52

Genetics Medicine Genetic Engineering Genetic Disease 52

Scienmag

MAY 27, 2021

Credit: NTU Singapore Scientists at Nanyang Technological University, Singapore (NTU Singapore) have developed a new biomaterial made entirely from discarded bullfrog skin and fish scales that could help in bone repair.

Scientist 54

Scientist Containment Development Engineer 54

The Pharma Data

OCTOBER 21, 2020

Title: Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria Poster #: PO0650. Synlogic will present the results of an effort to engineer a Synthetic Biotic bacterial strain, SYNB8802, to metabolize oxalate in the GI tract as a new treatment for enteric hyperoxaluria. 22-25, 2020.

Engineer 40

Engineer Containment Medicine Clinical Trials 40

The Pharma Data

OCTOBER 26, 2020

With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic therapeutics that target validated underlying biology to treat disease in new ways. Synlogic anticipates that subsequent events and developments will cause its views to change.

Clinical Trials 52

Clinical Trials Clinical Trials Containment Clinical Development 52

pharmaphorum

APRIL 26, 2022

Compared to a ‘critical organ’ that had been largely ignored, companies working to develop microbiome-based therapies believe there is untapped potential in the area. Ben Hargreaves speaks to companies that are developing therapies not just in gastrointestinal conditions but also in broader areas, such an immuno-oncology.

Containment 114

Containment Development Production Immune Response 114

pharmaphorum

MARCH 10, 2021

The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise a genetically engineered version of SARS-CoV-2 with the P.1 1 – that is worrying health officials around the world. . 1 mutations, as well as variants from the UK and South Africa.

Vaccination 65

Vaccination Vaccine Genetic Engineering Engineer 65

Scienmag

FEBRUARY 19, 2021

Undergraduate students explore a more efficient way to measure protein-containing vessels released by cells Credit: DGIST Despite our great progress in understanding various cellular mechanisms over the last decades, many of them remain unclear.

Containment 52

Containment RNA Protein Genetics 52

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein 52

Protein Vaccination Vaccine Antibody 52

The Pharma Data

JANUARY 13, 2021

NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the U.S. Harpoon has four drug product candidates in clinical development for the treatment of solid and hematologic malignancies based on its proprietary TriTAC platform. SOUTH SAN FRANCISCO, Calif., NYSE: ABBV).

Drugs 52

Drugs Clinical Trials Clinical Trials Containment 52

The Pharma Data

DECEMBER 15, 2020

Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 NEW HAVEN, Conn., Forward-Looking Statements.

Containment 52

Containment Protein Engineer Sales 52

The Pharma Data

NOVEMBER 9, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. “The

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52